Key Points
- Insider Giles Wilson bought 237 Dr. Martens shares at GBX 63 each, for a total of £149.31.
- Dr. Martens reported quarterly revenue of £290.4 million and EPS of GBX (1); analysts forecast full-year EPS of 2.58.
- Analysts have a “Moderate Buy” consensus and an average price target of GBX 105; the shares opened at GBX 54.10.
Dr. Martens plc (LON:DOCS - Get Free Report) insider Giles Wilson bought 237 shares of the business's stock in a transaction on Wednesday, November 11th. The shares were acquired at an average price of GBX 63 per share, for a total transaction of £149.31.
Dr. Martens Price Performance
Shares of LON DOCS opened at GBX 54.10 on Friday. The stock has a market capitalization of £517.88 million, a price-to-earnings ratio of 22.54, a PEG ratio of 6.40 and a beta of 0.26. The business has a 50-day moving average of GBX 66.75 and a 200-day moving average of GBX 69.42. Dr. Martens plc has a fifty-two week low of GBX 52.10 and a fifty-two week high of GBX 90. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13.
Dr. Martens (LON:DOCS - Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported GBX (1) EPS for the quarter. The company had revenue of £290.40 million during the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%. As a group, sell-side analysts predict that Dr. Martens plc will post 2.58 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Berenberg Bank reaffirmed a "buy" rating and set a GBX 110 target price on shares of Dr. Martens in a research note on Friday, October 9th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, Dr. Martens currently has a consensus rating of "Moderate Buy" and a consensus price target of GBX 105.
Check Out Our Latest Research Report on Dr. Martens
Dr. Martens Company Profile
(
Get Free Report)
Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
